1) Time. To get a positive BoM, placebo needs to get to 143-150 MACE before end of dosing (250 events). Using EXAMINE rates, we're already there. BoM rates should be equal or worse than EXAMINE, that potentially leaves RVX with a buffer.

Event model

2) Management's unwilligness to bring more dilution to the company. RVX is running on fumes, and while issuing 10M of stock for 30M$ should be the right thing to do, they don't do it.

3) Management's unwillingness to start other trials. Since 2017, all other trials are pushed back. In their shoes, if I thought BoM wouldnt succeed, I would have started other fires(trials) to make sure the company stays hot if BoM ends up a cold shower. I feel like the management is saying: No need for it, BoM will saves us some time for other trials.

4) Past trials success with 5-point MACE. I know it's not 1 for 1 between 5pts MACE and narrow 3pts MACE. But still. I'd rather have a drug that expresses less negative CVD events and the opposite.

Change my mind.